The epidermal growth factor receptor (EGFR)-targeted antibodies cetuximab and panitumumab can treat metastatic colorectal cancer (mCRC) negative for mutations in KRAS and NRAS exons 2–4 [4–6]. Here, EGFR is linked to metastatic colorectal cancer.